List view / Grid view
With over $7 billion sales predicted by 2029, AstraZeneca’s Tagrisso…
With over $7 billion sales predicted by 2029, AstraZeneca’s Tagrisso is set to lead the lung cancer small molecule treatment market, according to GlobalData.
As the pharmaceutical industry awaits the first regulatory approval of…
As the pharmaceutical industry awaits the first regulatory approval of an mRNA-based oncology therapy, research predicts BioNTech will lead the market by 2029, which by then, is anticipated to value $2 billion.
With antibody-drug conjugates (ADCs) gaining favour as oncology treatments, research…
With antibody-drug conjugates (ADCs) gaining favour as oncology treatments, research shows Daiichi Sankyo, Seagen and Roche are currently three of the market's most important players.
